Source:http://linkedlifedata.com/resource/pubmed/id/11495691
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-3
|
pubmed:dateCreated |
2001-8-9
|
pubmed:abstractText |
Adenoviral gene transfer is a promising tool for direct treatment of cystic fibrosis by local application of the CFTR-gene via the airway. However, various host defense mechanisms reduce the adenoviral infectivity and hereby the success of adenoviral transduction. Twenty-eight of 62 BALs from various patients exerted strong inhibition of adenoviral infection of 293 cells. This soluble activity could be attributed to larger peptides rather than to small molecules. Beside immunoglobulins, certain epithelial cell-derived anti-microbial polypeptides called defensins might be involved. Therefore, we investigated the inhibitory potential of the defensins HNP-1 and HBD-2 on adenoviral infectivity. 293 cells infected with adenovirus-type 5 were treated with both peptides. Compared to control, HNP-1 reduced adenoviral infection by more than 95% if administered at 50 microg/ml, and the IC50-value was 15 microg/ml. In contrast, HBD-2 was much less efficient and did not block adenoviral infection at doses up to 50 microg/ml. Our data demonstrate that the presence of certain polypeptides in the BAL, i.e. the defensin HNP-1, might be the major obstacle for adenoviral gene transfer, particularly in patients with inflammatory diseases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DEFB4A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Defensins,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Defensins,
http://linkedlifedata.com/resource/pubmed/chemical/human neutrophil peptide 1
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0167-0115
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
101
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
157-61
|
pubmed:dateRevised |
2010-9-17
|
pubmed:meshHeading |
pubmed-meshheading:11495691-Adenoviridae,
pubmed-meshheading:11495691-Antiviral Agents,
pubmed-meshheading:11495691-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:11495691-Cystic Fibrosis,
pubmed-meshheading:11495691-Dose-Response Relationship, Drug,
pubmed-meshheading:11495691-Gene Therapy,
pubmed-meshheading:11495691-Humans,
pubmed-meshheading:11495691-Lung Diseases,
pubmed-meshheading:11495691-Transduction, Genetic,
pubmed-meshheading:11495691-Tumor Cells, Cultured,
pubmed-meshheading:11495691-alpha-Defensins,
pubmed-meshheading:11495691-beta-Defensins
|
pubmed:year |
2001
|
pubmed:articleTitle |
Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro.
|
pubmed:affiliation |
Department of Internal Medicine, Christian-Albrechts-Universität Kiel, Kiel, Germany. andreas.bastian@uni-bochum.de
|
pubmed:publicationType |
Journal Article,
Comparative Study
|